Itraconazole Side Effects
Some side effects of itraconazole may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to itraconazole: oral capsule, oral solution, oral tablet
Get emergency medical help if you have any of these signs of an allergic reaction while taking itraconazole: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
ringing in your ears, problems with hearing;
numbness or tingly feeling, blurred vision, double vision, loss of bladder control;
pain or burning when you urinate;
nausea, pain in your upper stomach, itching, loss of appetite, weakness, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); or
severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate.
Other common side effects may include:
diarrhea, constipation, bloating, mild nausea;
unpleasant taste in your mouth;
mild itching or skin rash;
joint pain, muscle pain or weakness;
headache, dizziness; or
runny nose or other cold symptoms.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to itraconazole: intravenous kit, oral capsule, oral solution, oral tablet
In general, pooled data involving 15,000 patients suggest that adverse effects occur in approximately 7% of patients treated with itraconazole for 4 weeks or less, and up to 18% in patients treated for more than one month. Most reported adverse effects are transient and considered mild to moderate in nature.
Gastrointestinal side effects have included nausea (up to 11%), diarrhea (up to 11%), vomiting (7%), abdominal pain or discomfort (up to 6%), dyspepsia (up to 4%), flatulence (up to 4%), gingivitis (3%), constipation (up to 3%), ulcerative stomatitis (up to 3%), gastritis (2%), increased appetite (2%), gastroenteritis (2%), dysphagia (less than 2%), hemorrhoids (less than 2%), dysgeusia (less than 2%), and anorexia (1%). Cholestasis has been reported. Abdominal pain, pancreatitis, vomiting, dyspepsia, nausea, diarrhea, constipation, and dysgeusia have also been reported during postmarketing experience.
Metabolic side effects have included hypertriglyceridemia (up to 11%), hypokalemia (up to 9%), increased alkaline phosphatase (up to 2%), hypomagnesemia (up to 2%), increased lactate dehydrogenase (up to 2%), hypophosphatemia (1% to 2%), hyperglycemia (less than 2%), dehydration (less than 2%), decreased weight (less than 2%), fluid overload (1%), and hypocalcemia (1%). Hypertriglyceridemia and hypokalemia have also been reported during postmarketing experience.
Nervous system side effects have included headache (up to 10%), dizziness (up to 4%), hypoacusis (3.3%), tremor (1% to 2%), insomnia (less than 2%), tinnitus (less than 2%), vertigo (1%), and somnolence (1%). An elderly patient experienced visual hallucinations, confusion, and weakness after receiving itraconazole. The symptoms reappeared following accidental itraconazole doses 7 and 10 days later. Transient or permanent hearing loss, tinnitus, peripheral neuropathy, paresthesia, headache, dizziness, and hypoesthesia have been reported during postmarketing experience.
Respiratory side effects have included rhinitis (up to 9%), upper respiratory tract infection (up to 8%), sinusitis (up to 7%), coughing (up to 4%), pneumonia (2%), increased sputum (2%), dyspnea (up to 2%), pharyngitis (up to 2%), pulmonary infiltration (1% to 2%), and pharyngolaryngeal pain (1%). Pulmonary edema and dyspnea have been reported during postmarketing experience.
Other side effects have included fever (up to 7%), injury (up to 7%), edema (up to 4%), chest pain (3%), fatigue (up to 3%), malaise (up to 3%), pain (up to 3%), asthenia (up to 2%), rigors (less than 2%), back pain (less than 2%), hot flushes (less than 2%), and implantation complication (less than 2%). Peripheral edema and pyrexia have been reported during postmarketing experience.
Dermatologic side effects have included rash (up to 9%), pruritus (up to 5%), increased sweating (up to 3%), unspecified skin disorder (2.3%), and erythematous rash (1% to 2%). Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, exfoliative dermatitis, leukocytoclastic vasculitis, erythema multiforme, photosensitivity, rash, urticaria, pruritus, and alopecia have been reported during postmarketing experience.
Hepatic side effects have included bilirubinemia (up to 6%), abnormal liver function (up to 3%), increased SGPT/ALT (up to 3%), jaundice (up to 2%), increased SGOT/AST (up to 2%), increased gamma-glutamyltransferase (1% to 2%), and hepatitis (less than 2%). Mild, transient elevations in liver function tests have occurred in 1% to 7% of patients receiving continuous therapy. Rare cases of serious hepatotoxicity (including liver failure and death) and rare cases of reversible hepatitis (4 to 6 weeks after initiating itraconazole therapy) have been reported. Isolated cases of cholestatic jaundice have also been reported. Serious hepatotoxicity (including some cases of fatal acute liver failure), hepatitis, and reversible increases in hepatic enzymes have also been reported during postmarketing experience.
Hypersensitivity side effects have included rash and pruritus in up to 5% of treated patients (may be more likely in immunocompromised patients). Anaphylaxis; anaphylactic, anaphylactoid, and allergic reactions; serum sickness; and angioneurotic edema have been reported during postmarketing experience. At least one case of anaphylactic shock following long-term intravenous therapy has been reported.
Cardiovascular side effects have included hypertension (up to 3.2%), vein disorder (3%), abnormal electrocardiogram (1.4%), hypotension (1%), orthostatic hypotension (1%), vasculitis (1%), sinus bradycardia (1%), and tachycardia (up to 1%). Premature ventricular contractions have been reported. Congestive heart failure has been reported during postmarketing experience.
Local side effects associated with the intravenous formulation have included application site reaction (4%).
Renal side effects have included increased serum creatinine (up to 3%), abnormal renal function (1%), and increased blood urea nitrogen (up to 1%).
Psychiatric side effects have included depression (up to 3%), anxiety (3%), abnormal dreaming (2%), and decreased libido (up to 2%).
Genitourinary side effects have included cystitis (3%), urinary tract infection (up to 3%), albuminuria (less than 2%), hematuria (less than 2%), gynecomastia (less than 2%), male breast pain (less than 2%), bacteriuria (1.4%), impotence (1%), and menstrual disorders (infrequent). Urinary incontinence, pollakiuria, menstrual disorders, and erectile dysfunction have been reported during postmarketing experience.
Musculoskeletal side effects have included myalgia (up to 3%), bursitis (3%), and back pain (1.2%). Arthralgia and myalgia have been reported during postmarketing experience.
Hematologic side effects have included neutropenia, leukopenia, and thrombocytopenia during postmarketing experience.
Immunologic side effects have included Pneumocystis carinii infection (2%), herpes zoster (2%), and unspecified infection (less than 2%).
Endocrine side effects have included adrenal insufficiency (less than 2%).
Ocular side effects have included abnormal vision (less than 2%). Visual disturbances (including blurred vision and diplopia) have been reported during postmarketing experience.
More itraconazole resources
- itraconazole MedFacts Consumer Leaflet (Wolters Kluwer)
- itraconazole Advanced Consumer (Micromedex) - Includes Dosage Information
- Itraconazole Prescribing Information (FDA)
- Itraconazole Professional Patient Advice (Wolters Kluwer)
- Itraconazole Monograph (AHFS DI)
- Onmel Prescribing Information (FDA)
- Onmel MedFacts Consumer Leaflet (Wolters Kluwer)
- Sporanox Consumer Overview
- Sporanox Prescribing Information (FDA)
- Sporanox PulsePak MedFacts Consumer Leaflet (Wolters Kluwer)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.